Abstract
Objective Vectorcardiographic (VCG) global electrical heterogeneity (GEH) metrics showed clinical usefulness. We aimed to assess the reproducibility of GEH metrics.
Methods GEH was measured on two 10-second 12-lead ECGs recorded on the same day in 4,316 participants of the Multi-Ethnic Study of Atherosclerosis (age 69.4±9.4 y; 2317(54%) female, 1728 (40%) white, 1138(26%) African-American, 519(12%) Asian-American, 931(22%) Hispanic-American). GEH was measured on a median beat, comprised of the normal sinus (N), atrial fibrillation/flutter (S), and ventricular-paced (VP) beats. Spatial ventricular gradient’s (SVG’s) scalar was measured as sum absolute QRST integral (SAIQRST) and vector magnitude QT integral (VMQTi).
Results Two N ECGs with heart rate (HR) bias of -0.64 (95% limits of agreement [LOA] - 5.68 to 5.21) showed spatial area QRS-T angle (aQRST) bias of -0.12 (95%LOA -14.8 to 14.5). Two S ECGs with HR bias of 0.20 (95%LOA -15.8 to 16.2) showed aQRST bias of 1.37 (95%LOA -33.2 to 35.9). Two VP ECGs with HR bias of 0.25 (95%LOA -3.0 to 3.5) showed aQRST bias of -1.03 (95%LOA -11.9 to 9.9). After excluding premature arial or ventricular beat and two additional beats (before and after extrasystole), the number of cardiac beats included in a median beat did not affect the GEH reproducibility. Mean-centered log-transformed values of SAIQRST and VMQTi demonstrated perfect agreement (Bias 0; 95%LOA -0.092 to 0.092).
Conclusion GEH measurements on N, S, and VP median beats are reproducible. SVG’s scalar can be measured as either SAIQRST or VMQTi.
Significance Satisfactory reproducibility of GEH metrics supports their implementation.
Highlights
VCG metrics are reliably reproducible, which supports their implementation.
GEH is reproducible if measured during atrial fibrillation or ventricular pacing.
Scalar of spatial ventricular gradient can be measured as either SAIQRST or VMQTi.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
Not a clinical trial
Funding Statement
This research was supported by contracts 75N92020D00001, HHSN268201500003I, N01-HC-95159, 75N92020D00005, N01-HC-95160, 75N92020D00002, N01-HC-95161, 75N92020D00003, N01-HC-95162, 75N92020D00006, N01-HC-95163, 75N92020D00004, N01-HC-95164, 75N92020D00007, N01-HC-95165, N01-HC-95166, N01-HC-95167, N01-HC-95168 and N01-HC-95169 from the National Heart, Lung, and Blood Institute, and by grants UL1-TR-000040, UL1-TR-001079, and UL1-TR-001420 from the National Center for Advancing Translational Sciences (NCATS). The authors thank the other investigators, the staff, and the participants of the MESA study for their valuable contributions. A full list of participating MESA investigators and institutions can be found at http://www.mesa-nhlbi.org. This work was supported by the National Institutes of Health (HL118277), Medical Research Foundation of Oregon, and OHSU President Bridge funding (Tereshchenko), the National Center for Advancing Translational Sciences of the National Institutes of Health (UL1TR001420) (Soliman).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All MESA participants signed informed consent before entering the MESA study. All MESA protocols were reviewed and approved by the local MESA field center IRBs. The current study protocol was approved by the Oregon Health & Science University (OHSU) institutional review board.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The MESA Study data are available through the National Heart, Lung, and Blood Institute's Biological Specimen and Data Repository Information Coordinating Center (BioLINCC), the National Center of Biotechnology Information's database of Genotypes and Phenotypes (dbGaP), and via MESA Coordinating Center at the University of Washington. The open-source MATLAB (MathWorks, Natick, MA, USA) code is provided at https://physionet.org/physiotools/geh & https://github.com/Tereshchenkolab/Origin. Open-source STATA code was provided at https://github.com/Tereshchenkolab/statistics.
